By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

SCHOTT Pharma AG & Co. KGaA (1SXP.F)

XETRA Currency in EUR
€26.25
-€0.05
-0.19%
Last Update: 8 Jul 2025, 07:13
€3.95B
Market Cap
39.18
P/E Ratio (TTM)
0.61%
Forward Dividend Yield
€19.82 - €36.18
52 Week Range

1SXP.F Stock Price Chart

Explore SCHOTT Pharma AG & Co. KGaA interactive price chart. Choose custom timeframes to analyze 1SXP.F price movements and trends.

There is nothing to show.

1SXP.F Company Profile

Discover essential business fundamentals and corporate details for SCHOTT Pharma AG & Co. KGaA (1SXP.F) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

IPO Date

26 Sept 2023

Employees

4.75K

CEO

Andreas Reisse

Description

SCHOTT Pharma AG & Co. KGaA develops, produces, and sells drug containment solutions and delivery systems for injectable drugs to the pharmaceutical and biotechnology industries worldwide. The company offers polymer and glass syringes, ampoules, vials, and cartridges. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container. The company's cartridge products comprise cartriQ, a pharmaceutical glass cartridge for peptide and protein-based injectables; cartriQ Large Volume, a pharmaceutical glass cartridge for large-volume injectables; Cartridges Double Chamber, a pharmaceutical glass cartridge for lyophilized drugs; Cartridges Break Resistant, a pharmaceutical glass cartridge; and TopLine and StandardLine cartridges. Its vial products include adaptiQ, a pharmaceutical glass vial for injectables; EVERIC pure, a pharmaceutical glass vial for unmatched drug stability; EVERIC care, a pharmaceutical glass vial for a pH range; EVERIC strong & smooth, a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for lyophilized drugs; and TopLine and StandardLine vials. Its ampoule products comprise Ampoules easyOPC, a pharmaceutical glass ampoule for ampoule opening; Ampoules Anti-Counterfeiting, a pharmaceutical glass ampoule for protection against drug counterfeiting; and StandardLine ampoules. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

1SXP.F Financial Timeline

Browse a chronological timeline of SCHOTT Pharma AG & Co. KGaA corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 May 2026

Upcoming earnings on 11 Feb 2026

Upcoming earnings on 11 Dec 2025

Upcoming earnings on 12 Aug 2025

EPS estimate is €0.28, while revenue estimate is €261.90M.

Earnings released on 15 May 2025

EPS came in at €0.25 surpassing the estimated €0.23 by +7.89%, while revenue for the quarter reached €252.33M, beating expectations by +6.33%.

Earnings released on 13 Feb 2025

EPS came in at €0.19 falling short of the estimated €0.22 by -13.64%, while revenue for the quarter reached €229.84M, missing expectations by -3.22%.

Dividend declared on 5 Feb 2025

A dividend of €0.16 per share was announced, adjusted to €0.16. The dividend was paid on 7 Feb 2025.

Earnings released on 12 Dec 2024

EPS came in at €0.24 falling short of the estimated €0.26 by -5.76%, while revenue for the quarter reached €957.09M, beating expectations by +278.90%.

Earnings released on 29 Aug 2024

EPS came in at €0.29 surpassing the estimated €0.20 by +48.99%, while revenue for the quarter reached €253.59M, beating expectations by +16.85%.

Earnings released on 27 Jun 2024

EPS came in at €0.17 falling short of the estimated €0.21 by -19.79%, while revenue for the quarter reached €234.20M, beating expectations by +0.02%.

Dividend declared on 15 Mar 2024

A dividend of €0.15 per share was announced, adjusted to €0.15. The dividend was paid on 19 Mar 2024.

Earnings released on 29 Feb 2024

EPS came in at €0.30 surpassing the estimated €0.27 by +12.02%, while revenue for the quarter reached €232.00M, missing expectations by -1.54%.

Earnings released on 26 Jan 2024

EPS came in at €0.23 surpassing the estimated €0.16 by +43.75%, while revenue for the quarter reached €228.52M, missing expectations by -0.02%.

Earnings released on 30 Jun 2023

EPS came in at €0.20, while revenue for the quarter reached €221.35M.

Earnings released on 30 Mar 2023

EPS came in at €0.32, while revenue for the quarter reached €223.52M.

Earnings released on 30 Dec 2022

EPS came in at €0.25, while revenue for the quarter reached €225.22M.

Earnings released on 30 Sept 2022

EPS came in at €0.17, while revenue for the quarter reached €203.04M.

1SXP.F Stock Performance

Access detailed 1SXP.F performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
1SXP.F
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
1SXP.F
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More